Expanded access to Mepsevii for MPS VII
Part of Genetic & congenital, Hormones & metabolism, Skin clinical trials.
This program provides access to Mepsevii, an enzyme replacement therapy, for people with MPS VII who cannot get the drug through their regular healthcare system. It is a way to try the treatment outside of a clinical trial.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of MPS VII (Sly syndrome).
- You cannot be enrolled in another clinical trial for MPS VII.
- Mepsevii must not be commercially available or accessible to you in your country.
- Your doctor must request this expanded access program for you.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial enrolls people with mucopolysaccharidosis type VII (MPS VII) to track their health over time. It may help your care team better understand how the condition behaves and how monitoring should be done.
This study follows people with MPS, a rare genetic condition, to learn more about the disease over time. If you have a confirmed MPS diagnosis, you may be able to join.
This Phase 1 trial tests an enzyme replacement treatment given to a developing baby before birth for specific inherited “lysosomal storage” diseases. The goal is to see if the treatment is safe and can improve outcomes for babies diagnosed in pregnancy.
This early-stage trial tests JR-446, a new treatment for MPS IIIB, a rare genetic disorder that affects the brain and body. The treatment is delivered directly into the fluid around the spinal cord and aims to slow or improve symptoms in young children.
This program provides early access to an experimental enzyme therapy given directly into the brain for children with Sanfilippo syndrome type B, a genetic condition that affects the nervous system. The treatment aims to replace a missing enzyme to slow or stabilize symptoms.
This study tests a new gene therapy called JWK008 for adults with MPS type I. The goal is to see if it is safe and can help improve symptoms. You may be able to join if you are 18 or older and have not had serious side effects from enzyme replacement therapy.
Hear when a new Mucopolysaccharidosis VII trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.